证券代码：688739 证券简称：成大生物 公告编号：2026-018 关于公司独立董事任期届满离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、独立董事离任情况 辽宁成大生物股份有限公司（以下简称"公司"）董事会近日收到独立董事 陈克兢先生、刘晓辉先生、张克坚先生提交的书面辞职报告。上述人员自 2020 年 3 月履职以来，连续任职已满六年，根据相关规定及任期安排申请离任。根据 《上市公司独立董事管理办法》相关规定，三位独立董事申请辞去公司第五届董 事会独立董事职务，同时一并辞去其在董事会审计委员会、薪酬与考核委员会、 提名委员会、战略委员会中担任的相应职务。本次辞职自新任独立董事补选完成 之日起生效，辞职生效后将不再担任公司任何职务。截至本公告披露日，陈克兢 先生、张克坚先生未持有公司股份；刘晓辉先生持有公司股份 20,000 股。 | | | | 原定任 | | 是否继续 在上市公 | 是否存在 | | --- | --- | --- | --- | --- | --- | --- | | 姓 | 离任职务 ...

一、本次检查相关信息 企业名称：成大生物（本溪）有限公司 生产地址：辽宁省本溪市高新技术产业开发区仙榆路 6 号 检查范围： 证券代码：688739 证券简称：成大生物 公告编号：2026-017 辽宁成大生物股份有限公司 关于全资子公司通过药品 GMP 符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 辽宁成大生物股份有限公司（以下简称"公司"）全资子公司成大生物（本 溪）有限公司（以下简称"本溪子公司"）近日收到辽宁省药品监督管理局签发 的《药品 GMP 符合性现场检查结果通知书》（编号：辽 26010013）。本溪子公司 生产基地生产的冻干人用狂犬病疫苗（人二倍体细胞）已通过药品生产质量管理 规范符合性检查（以下简称"本次检查"）。现将相关情况公告如下： 本溪子公司本次通过药品 GMP 符合性检查，标志着其生产基地已具备冻干人 用狂犬病疫苗（人二倍体细胞）商业化生产条件，生产质量管理体系符合药品监 管相关规范要求。本次检查通过有利于进一步完善公司疫苗生产体系与质量管控 能力，保障产品稳定供应，持续提升 ...

公司于2025年6月19日召开第五届董事会第十九次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》。公司拟使用不低于人民币1,000万 元（含）且不超过人民币2,000万元（含）的超募资金以集中竞价交易方式回购公 司人民币普通股股票，用于实施员工持股计划或股权激励，回购股份的价格为不 超过人民币38.00元/股（含），回购股份期限为自公司董事会审议通过本次回购股 份方案之日起不超过12个月。具体内容详见公司于2025年6月20日在上海证券交易 所网站（www.sse.com.cn）披露的《辽宁成大生物股份有限公司关于以集中竞价交 易方式回购公司股份的回购报告书》（公告编号：2025-034）。 证券代码：688739 证券简称：成大生物 公告编号：2026-016 辽宁成大生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | --- | --- | --- | --- ...

- The report introduces a comprehensive impact coefficient model to measure the influence of index rebalancing on individual stocks, particularly focusing on the March 2026 adjustments for key indices such as STAR 50, STAR-ChiNext 50, STAR 100, Dividend Low Volatility 100, and Beijing Stock Exchange 50[9][11][14] - The comprehensive impact coefficient is defined as follows: $ effect\_total_{s}=\sum_{i=1}^{n}\frac{wt\_chg_{s_{i}}\times fund\_size_{i}}{amount\_avg_{s_{i}}20} $ where: - $ wt\_chg_{s_{i}} $ represents the weight change of stock $ s $ in index $ i $ - $ fund\_size_{i} $ is the tracking scale of index $ i $ - $ amount\_avg_{s_{i}}20 $ is the average trading volume of stock $ s $ over the past 20 days[11] - The model evaluates the impact of passive trading caused by index rebalancing, emphasizing that larger indices with higher tracking scales (e.g., STAR 50 with 1489 billion RMB) generate more significant passive trading effects, creating potential investment opportunities for stocks added to these indices[13][14] - The report provides detailed calculations of the comprehensive impact coefficients for stocks with significant adjustments, identifying stocks like Jikang Technology (impact coefficient: 5.95), Zhongke Feice (impact coefficient: 1.73), and Taoli Bread (impact coefficient: 1.55) as having notable positive impacts due to their inclusion in indices such as Beijing Stock Exchange 50 and STAR 50[14][17] - Stocks removed from indices also exhibit negative impact coefficients, such as Weida Optoelectronics (-2.95), Jike Shares (-2.65), and Junshi Biosciences (-1.73), reflecting the adverse effects of exclusion from key indices[17]

Financial Performance Summary - In 2025, the company reported a total operating revenue of 139,028.74 million RMB, representing a year-on-year decrease of 17.06% [1] - The net profit attributable to the parent company was 13,761.67 million RMB, down 59.86% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 4,599.98 million RMB, a decline of 85.79% year-on-year [1] - Basic earnings per share were 0.33 RMB, reflecting a decrease of 60.24% compared to the previous year [1] Asset and Equity Overview - As of the end of the reporting period, total assets amounted to 975,181.82 million RMB, a decrease of 2.98% from the beginning of the period [2] - The equity attributable to the parent company was 935,998.52 million RMB, down 2.12% from the beginning of the period, primarily due to dividend distribution and stock buybacks [2] Factors Affecting Performance - The decline in operating revenue was mainly influenced by changes in the domestic rabies vaccine market, including regulatory policy changes and intensified market competition, leading to reduced market demand [2] - Increased asset impairment losses were due to the company's strategic adjustment in R&D, specifically the termination of the hib vaccine project, resulting in full impairment of capitalized R&D investments [2] - The increase in fair value changes was attributed to the recovery in asset valuations within the innovative drug sector of the private equity investments [2] - The company experienced growth in overseas sales and managed to control selling and administrative expenses effectively, which helped mitigate some downward pressure on performance [2]

Group 1 - The company, Chengda Biology, announced a projected total operating revenue of 1,390.29 million yuan for 2025, representing a year-on-year decline of 17.06% [2] - The net profit attributable to the parent company's shareholders is expected to be 137.62 million yuan, reflecting a significant year-on-year decrease of 59.86% [2]

Core Viewpoint - Chengda Biotech (688739.SH) reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the domestic rabies vaccine market and strategic adjustments in R&D [1] Group 1: Financial Performance - The company achieved an operating revenue of 1.39 billion yuan, a year-on-year decrease of 17.06% [1] - The net profit attributable to the parent company was 138 million yuan, reflecting a year-on-year decline of 59.86% [1] Group 2: Factors Affecting Performance - The decline in operating revenue was primarily due to changes in the domestic human rabies vaccine market, influenced by regulatory policy changes and intensified market competition, leading to reduced market demand [1] - Increased asset impairment losses were mainly due to the company's strategic adjustment in R&D, resulting in the termination of the hib vaccine project and full impairment of capitalized R&D investments related to that project [1] - The increase in fair value gains was attributed to the recovery in asset valuations within the innovative drug sector of the private equity funds the company invested in [1] - The company experienced growth in overseas sales revenue and managed to mitigate some downward pressure on performance through effective control of sales and management expenses [1]

Core Viewpoint - Chengda Biotech (688739.SH) reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the domestic rabies vaccine market and strategic adjustments in R&D [1] Group 1: Financial Performance - The company achieved an operating revenue of 1.39 billion yuan, a year-on-year decrease of 17.06% [1] - The net profit attributable to the parent company was 138 million yuan, reflecting a year-on-year decline of 59.86% [1] Group 2: Factors Affecting Performance - The decline in operating revenue was primarily due to changes in the domestic human rabies vaccine market, influenced by regulatory policy changes and intensified market competition, leading to reduced market demand [1] - There was an increase in asset impairment losses, mainly due to the company's strategic adjustment in R&D, resulting in the termination of the Hib vaccine project and full impairment of capitalized R&D investments related to that project [1] - An increase in fair value gains was noted, attributed to the recovery in asset valuations of investments in private equity funds focused on the innovative drug sector [1] - The company experienced growth in overseas sales revenue and managed to mitigate some downward pressure on performance through effective internal management and control of sales and administrative expenses [1]

Financial Performance - Total revenue for 2025 was RMB 139,028.74 million, a decrease of 17.06% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was RMB 13,761.67 million, down 59.86% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 4,599.98 million, a decline of 85.79%[4] - Basic earnings per share decreased to RMB 0.33, down 60.24% from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 975,181.82 million, a decrease of 2.98% from the beginning of the period[5] - Equity attributable to shareholders of the parent company was RMB 935,998.52 million, down 2.12% from the beginning of the period[5] Market and Operational Factors - The decline in revenue was primarily due to changes in the domestic rabies vaccine market environment and increased competition[5] - Increased asset impairment losses were due to the termination of the hib vaccine project and full impairment of capitalized R&D investments[5] - The company experienced growth in overseas sales revenue and managed to control selling and administrative expenses effectively[5] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to final confirmation in the annual report[7]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, primarily due to changes in the domestic rabies vaccine market and strategic adjustments in research and development [1] Group 1: Financial Performance - The company achieved total operating revenue of 1.39 billion yuan, a year-on-year decrease of 17.06% [1] - Net profit for the year was 138 million yuan, reflecting a year-on-year decline of 59.86% [1] Group 2: Factors Affecting Performance - Revenue decline was mainly influenced by changes in the domestic rabies vaccine market, including regulatory policy changes and intensified market competition, leading to reduced market demand [1] - The increase in asset impairment losses was primarily due to the company's strategic adjustment in R&D, resulting in the termination of the hib vaccine project and full impairment of capitalized R&D investments [1] - The increase in fair value gains was attributed to the recovery in asset valuations within the innovative drug sector of the private equity funds the company invested in [1] - The company experienced growth in overseas sales revenue and managed to mitigate some of the downward pressure on performance through effective control of sales and management expenses [1]